Please use this identifier to cite or link to this item: http://hdl.handle.net/10201/72040

Title: Detection and characterisation of disseminated tumour cells in bone marrow of breast cancer patients by immunostaining of Her-2 and MUC-1 in combination with Thomsen-Friedenreich (CD176)
Issue Date: 2014
Publisher: F. Hernández y Juan F. Madrid. Universidad de Murcia. Departamento de Biología Celular e Histología
Citation: Histology & Histopathology, Vol. 19, nº 7 (2014)
ISSN: 1699-5848
0213-3911
Related subjects: CDU::6 - Ciencias aplicadas::61 - Medicina
Keywords: Imunostaining
Bone marrow
DTCs
Thomsen-Friedenreich-antigen
Abstract: Disseminated tumour cells (DTCs) in the bone marrow derive from many primary tumours, such as breast cancer. Their mere existence hints to present or future metastasis and implicates a worse prognosis for the patient. DTCs may possess different characteristics in comparison to the primary tumour due to events like Epithelial-Mesenchymal-Transition. Therefore these cells might be able to survive chemotherapy and cause relapses of the disease at a later point. We aimed to detect and further characterise DTCs by an immunostaining approach with three different antigen markers (Her-2, MUC-1 and TF, also known as CD176). For that reason, bone marrow of 41 breast cancer patients was obtained during surgery; DTCs were enriched by density gradient centrifugation and cytospins were prepared. After fixation, immunofluorescent double-stainings were carried out with antibodies against CD176 in combination with HER-2 or MUC-1. Cells co-expressing two antigens were found in all staining combinations (Her-2 and CD176: 46.14%; MUC-1 and CD176: 18.15% of all cases). Cells that stained for a single antigen only were also found (Her-2: 36.86%; MUC-1: 34.45%; CD176: 29.65% of all cases). Significant correlations between the stainings of all markers could be shown (p<0,001). In conclusion, Thomsen-Friedenreich Antigen (TF, CD176) is a promising marker in combination with the established marker Her-2 and other markers like MUC-1. These results may serve as a basis for future DTC detection routines and help to individualize medical treatment, reducing side effects and increasing the efficiency of the therapy.
Primary author: Andergassen, Ulrich
Kölbl, A. C.
Zebisch, M.
Heublein, Sabine
Hutter, S.
Ilmer, M.
Schindlbeck, C.
Friese, K.
Jeschke, U.
URI: http://hdl.handle.net/10201/72040
Document type: info:eu-repo/semantics/article
Number of pages / Extensions: 11
Rights: info:eu-repo/semantics/openAccess
Attribution-NonCommercial-NoDerivatives 4.0 International
Appears in Collections:Vol.29, nº 7 (2014)

Files in This Item:
File Description SizeFormat 
Andergassen-29-913-923-2014.pdf6,89 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons